NYSE American · Medical Instruments & Supplies · USD
Regentis Biomaterials Ltd. (RGNT) Stock Analysis
Regentis Biomaterials Ltd. (RGNT) is a Medical Instruments & Supplies stock listed on NYSE American and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
RGNT Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.51
- Previous Close
- $1.47
- Day's Range
- 1.49–1.56
- 52-Week Range
- 1.23–15.50
- Volume
- 14.16K
Valuation
- Market Cap
- $10.47M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −2.46
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$13.65M−384.27%
- Shares Outstanding
- 7.02M
Dividend and dates
- Avg Volume
- 56.68K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
Regentis Biomaterials Ltd. (RGNT) has a market capitalization of $10.47M.
In fiscal 2025, RGNT reported revenue of $0.00.
RGNT Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −77.89% |
| 2025 (partial year) | −10.13% |
As of October 21, 2026.
RGNT Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$13.65M | — |
| 2024 | $0.00 | $4.80M | — |
| 2023 | $0.00 | −$4.13M | — |
| 2022 | $0.00 | −$1.45M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$8.62M | −$13.65M | — |
| 2024 | $0.00 | — | $932.00K | $4.80M | — |
| 2023 | $0.00 | — | −$1.93M | −$4.13M | — |
| 2022 | $0.00 | — | −$1.41M | −$1.45M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal
YahooRegentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City
YahooIBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.
YahooRegentis Biomaterials (RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair
YahooRegentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
YahooRegentis Biomaterials H1 EPS $(0.44) Up From $(1.17) YoY
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Medical Instruments & Supplies Stocks
Intuitive Surgical, Inc.
$151.25B
BDXBecton, Dickinson and Company
$52.79B
MDLNMedline Inc.
$47.51B
RMDResMed Inc.
$34.63B
ALCAlcon Inc.
$32.60B
WSTWest Pharmaceutical Services, Inc.
$27.69B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B